Two novel Pt(IV) prodrug complexes, Pt(IV)-biSi-1 and Pt(IV)-biSi-2, are reported. Pt(IV)-biSi-2 demonstrated enhanced cytotoxicity against colon cancer cells (HCT 116 and HT-29) compared to cisplatin and Pt(IV)-biSi-1, with lower toxicity on nontumorigenic intestinal cells (HIEC6). The dataset was authored by Francisco Navas and last updated on 2026-05-31.
Use Cases
- Compare cytotoxicity profiles based on in vitro results against HCT 116 and HT-29 cell lines.
- Evaluate therapeutic index based on differential toxicity between cancer and nontumorigenic HIEC6 cells.
- Analyze DNA damage mechanisms based on descriptions of permanent double-strand breaks marked by histone gH2Ax.
- Assess prodrug reduction kinetics based on the faster reduction of Pt(IV)-biSi-2 to Pt(II) species.
- Model preclinical efficacy based on tumor growth reduction data from mouse models of colorectal cancer.
Strengths
- Includes comparative cytotoxicity data for two novel compounds against cisplatin and each other.
- Provides mechanistic insights into DNA damage effects, contrasting permanent vs. transient damage.
- Contains preclinical in vivo data from mouse models showing tumor growth reduction.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
- Data may reflect the specific experimental bias inherent to the described study.
Provenance
- Source
- e-cienciaDatos Harvested Dataverse
- Freshness
- Last updated 2026-05-31 04:10:09; freshness should be verified.